{"id":14364,"date":"2025-12-15T18:14:31","date_gmt":"2025-12-15T18:14:31","guid":{"rendered":"https:\/\/latamreports.com\/br\/?p=14364"},"modified":"2025-12-15T18:14:33","modified_gmt":"2025-12-15T18:14:33","slug":"anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao","status":"publish","type":"post","link":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/","title":{"rendered":"Anvisa libera uso da semaglutida para tratar gordura no f\u00edgado com inflama\u00e7\u00e3o"},"content":{"rendered":"\n

A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria<\/a> aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento passa a ser autorizado para o tratamento da gordura no f\u00edgado associada \u00e0 inflama\u00e7\u00e3o, condi\u00e7\u00e3o conhecida como esteatohepatite associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica (MASH).<\/p>\n\n\n\n

At\u00e9 ent\u00e3o, a semaglutida era aprovada no Brasil apenas para obesidade e controle de peso. Agora, o uso do Wegovy 2,4 mg est\u00e1 indicado para adultos com fibrose hep\u00e1tica moderada a avan\u00e7ada, desde que n\u00e3o haja cirrose.<\/p>\n\n\n\n

A decis\u00e3o marca um avan\u00e7o relevante no tratamento de uma doen\u00e7a silenciosa, que afeta milh\u00f5es de pessoas e costuma ser diagnosticada tardiamente.<\/p>\n\n\n\n

Doen\u00e7a comum, mas pouco percebida<\/h2>\n\n\n\n

A gordura no f\u00edgado atinge cerca de 30% da popula\u00e7\u00e3o adulta no mundo. Em muitos casos, est\u00e1 diretamente associada ao sobrepeso, \u00e0 obesidade e \u00e0 resist\u00eancia \u00e0 insulina. Estima-se que oito em cada dez pessoas com excesso de peso tenham algum grau da condi\u00e7\u00e3o.<\/p>\n\n\n\n

Quando evolui para a forma inflamat\u00f3ria, o risco aumenta. A MASH pode levar \u00e0 fibrose, cirrose, c\u00e2ncer hep\u00e1tico e at\u00e9 \u00e0 necessidade de transplante. Al\u00e9m disso, pacientes com a doen\u00e7a apresentam maior risco cardiovascular, incluindo infarto e AVC.<\/p>\n\n\n\n

No entanto, como os sintomas costumam ser discretos ou inexistentes no in\u00edcio, o diagn\u00f3stico frequentemente ocorre em fases mais avan\u00e7adas.<\/p>\n\n\n\n

Como a semaglutida atua nesse cen\u00e1rio<\/h2>\n\n\n\n

A semaglutida \u00e9 um an\u00e1logo do GLP-1, horm\u00f4nio envolvido no controle do apetite e do metabolismo da glicose. Inicialmente desenvolvida para tratar diabetes tipo 2, a subst\u00e2ncia ganhou destaque pelo efeito consistente na perda de peso.<\/p>\n\n\n\n

Agora, os estudos mostram que os benef\u00edcios v\u00e3o al\u00e9m do emagrecimento. Segundo especialistas, a redu\u00e7\u00e3o da gordura corporal e a melhora do perfil metab\u00f3lico ajudam a diminuir o ac\u00famulo de gordura no f\u00edgado e a inflama\u00e7\u00e3o cr\u00f4nica do \u00f3rg\u00e3o.<\/p>\n\n\n\n

Para hepatologistas e endocrinologistas, a nova indica\u00e7\u00e3o representa uma possibilidade concreta de frear a progress\u00e3o da doen\u00e7a e reduzir complica\u00e7\u00f5es graves no longo prazo.<\/p>\n\n\n\n

Resultados que embasaram a aprova\u00e7\u00e3o<\/p>\n\n\n\n

A autoriza\u00e7\u00e3o da Anvisa se baseou no estudo cl\u00ednico de fase 3 ESSENCE. A pesquisa avaliou 1.200 pacientes com MASH e fibrose nos est\u00e1gios 2 ou 3, sem cirrose.<\/p>\n\n\n\n

Os participantes receberam semaglutida 2,4 mg ou placebo, uma vez por semana, al\u00e9m do tratamento padr\u00e3o. Ap\u00f3s 72 semanas, os resultados mostraram diferen\u00e7a significativa.<\/p>\n\n\n\n

Entre os pacientes tratados com o medicamento, 63% apresentaram resolu\u00e7\u00e3o da inflama\u00e7\u00e3o hep\u00e1tica. No grupo placebo, o \u00edndice foi de 34,3%. Al\u00e9m disso, 37% dos pacientes que usaram semaglutida tiveram melhora da fibrose, contra 22,4% no grupo controle. Em um ter\u00e7o dos casos, os dois efeitos positivos ocorreram ao mesmo tempo.<\/p>\n\n\n\n

A segunda etapa do estudo segue em andamento e vai avaliar se o medicamento reduz eventos cl\u00ednicos graves relacionados ao f\u00edgado. Os dados finais s\u00e3o esperados para 2029.<\/p>\n\n\n\n

O que muda na pr\u00e1tica<\/h2>\n\n\n\n

Com a nova indica\u00e7\u00e3o, o Wegovy passa a ser uma op\u00e7\u00e3o terap\u00eautica espec\u00edfica para pacientes com MASH e fibrose moderada a avan\u00e7ada. Ainda assim, o tratamento deve ser associado a mudan\u00e7as no estilo de vida, como alimenta\u00e7\u00e3o adequada e atividade f\u00edsica regular.<\/p>\n\n\n\n

Especialistas tamb\u00e9m destacam o desafio do acesso. O custo elevado do medicamento ainda \u00e9 uma barreira para grande parte da popula\u00e7\u00e3o. Por isso, entidades m\u00e9dicas defendem discuss\u00f5es com o poder p\u00fablico e a ind\u00fastria para ampliar o alcance da terapia.<\/p>\n","protected":false},"excerpt":{"rendered":"

A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento passa a ser autorizado para o tratamento … Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":14365,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[31],"class_list":["post-14364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-negocios","tag-brasil","resize-featured-image"],"yoast_head":"\nAnvisa libera uso da semaglutida para tratar gordura<\/title>\n<meta name=\"description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa libera uso da semaglutida para tratar gordura\" \/>\n<meta property=\"og:description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento\" \/>\n<meta property=\"og:url\" content=\"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/\" \/>\n<meta property=\"og:site_name\" content=\"LatAm Reports\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/latamreports\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T18:14:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T18:14:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/latamreports.com\/br\/wp-content\/uploads\/anvisa-semaglutida.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LatAm Reports Redatores da Equipe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@latamreports\" \/>\n<meta name=\"twitter:site\" content=\"@latamreports\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LatAm Reports Redatores da Equipe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/\"},\"author\":{\"name\":\"LatAm Reports Redatores da Equipe\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\"},\"headline\":\"Anvisa libera uso da semaglutida para tratar gordura no f\u00edgado com inflama\u00e7\u00e3o\",\"datePublished\":\"2025-12-15T18:14:31+00:00\",\"dateModified\":\"2025-12-15T18:14:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/\"},\"wordCount\":605,\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/anvisa-semaglutida.png\",\"keywords\":[\"Brasil\"],\"articleSection\":[\"Neg\u00f3cios\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/\",\"name\":\"Anvisa libera uso da semaglutida para tratar gordura\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/anvisa-semaglutida.png\",\"datePublished\":\"2025-12-15T18:14:31+00:00\",\"dateModified\":\"2025-12-15T18:14:33+00:00\",\"description\":\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#primaryimage\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/anvisa-semaglutida.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/anvisa-semaglutida.png\",\"width\":1200,\"height\":630,\"caption\":\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa libera uso da semaglutida para tratar gordura no f\u00edgado com inflama\u00e7\u00e3o\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"name\":\"LatAm Reports\",\"description\":\"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas\",\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/latamreports.com\\\/br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\",\"name\":\"LatAm Reports\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"width\":2522,\"height\":1014,\"caption\":\"LatAm Reports\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/latamreports\",\"https:\\\/\\\/x.com\\\/latamreports\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\",\"name\":\"LatAm Reports Redatores da Equipe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"caption\":\"LatAm Reports Redatores da Equipe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa libera uso da semaglutida para tratar gordura","description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/","og_locale":"en_US","og_type":"article","og_title":"Anvisa libera uso da semaglutida para tratar gordura","og_description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento","og_url":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/","og_site_name":"LatAm Reports","article_publisher":"https:\/\/facebook.com\/latamreports","article_published_time":"2025-12-15T18:14:31+00:00","article_modified_time":"2025-12-15T18:14:33+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/anvisa-semaglutida.png","type":"image\/png"}],"author":"LatAm Reports Redatores da Equipe","twitter_card":"summary_large_image","twitter_creator":"@latamreports","twitter_site":"@latamreports","twitter_misc":{"Written by":"LatAm Reports Redatores da Equipe","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#article","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/"},"author":{"name":"LatAm Reports Redatores da Equipe","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70"},"headline":"Anvisa libera uso da semaglutida para tratar gordura no f\u00edgado com inflama\u00e7\u00e3o","datePublished":"2025-12-15T18:14:31+00:00","dateModified":"2025-12-15T18:14:33+00:00","mainEntityOfPage":{"@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/"},"wordCount":605,"publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"image":{"@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/anvisa-semaglutida.png","keywords":["Brasil"],"articleSection":["Neg\u00f3cios"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/","url":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/","name":"Anvisa libera uso da semaglutida para tratar gordura","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#primaryimage"},"image":{"@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/anvisa-semaglutida.png","datePublished":"2025-12-15T18:14:31+00:00","dateModified":"2025-12-15T18:14:33+00:00","description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento","breadcrumb":{"@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#primaryimage","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/anvisa-semaglutida.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/anvisa-semaglutida.png","width":1200,"height":630,"caption":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria aprovou nesta segunda-feira (15) uma nova indica\u00e7\u00e3o para a semaglutida. O medicamento"},{"@type":"BreadcrumbList","@id":"https:\/\/latamreports.com\/br\/anvisa-libera-uso-da-semaglutida-para-tratar-gordura-no-figado-com-inflamacao\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/latamreports.com\/br\/"},{"@type":"ListItem","position":2,"name":"Anvisa libera uso da semaglutida para tratar gordura no f\u00edgado com inflama\u00e7\u00e3o"}]},{"@type":"WebSite","@id":"https:\/\/latamreports.com\/br\/#website","url":"https:\/\/latamreports.com\/br\/","name":"LatAm Reports","description":"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas","publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/latamreports.com\/br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/latamreports.com\/br\/#organization","name":"LatAm Reports","url":"https:\/\/latamreports.com\/br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","width":2522,"height":1014,"caption":"LatAm Reports"},"image":{"@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/latamreports","https:\/\/x.com\/latamreports"]},{"@type":"Person","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70","name":"LatAm Reports Redatores da Equipe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","caption":"LatAm Reports Redatores da Equipe"}}]}},"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/14364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/comments?post=14364"}],"version-history":[{"count":1,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/14364\/revisions"}],"predecessor-version":[{"id":14366,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/14364\/revisions\/14366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media\/14365"}],"wp:attachment":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media?parent=14364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/categories?post=14364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/tags?post=14364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}